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Abstract
Introduction: Enteral nutrition (EN) with eicosapentaenoic acid (EPA)/g-linolenic acid (GLA) is recommended for
mechanically ventilated patients with severe lung injury. EPA/GLA has anti-inflammatory benefits, as evidenced by
its association with reduction in pulmonary inflammation, improvement in oxygenation and improved clinical
outcomes in patients with severe forms of acute lung injury. This study was a prospective, multicenter, randomized,
double-blinded, controlled trial designed to investigate whether EPA/GLA could have an effective role in the
treatment of patients with early sepsis (systemic inflammatory response syndrome with confirmed or presumed
infection and without any organ dysfunction) by reducing the progression of the disease to severe sepsis (sepsis
associated with at least one organ failure) or septic shock (sepsis associated with hypotension despite adequate
fluid resuscitation). Secondary outcomes included the development of individual organ failure, increased ICU and
hospital length of stay, need for mechanical ventilation and 28-day all-cause mortality.
Methods: Randomization was concealed, and patients were allocated to receive, for seven days, either an EPA/GLA
diet or an isocaloric, isonitrogenous control diet not enhanced with lipids. Patients were continuously tube-fed at a
minimum of 75% of basal energy expenditure × 1.3. To evaluate the progression to severe sepsis and/or septic
shock, daily screening for individual organ failure was performed. All clinical outcomes were recorded during a 28-
day follow-up period.
Results: A total of 115 patients in the early stages of sepsis requiring EN were included, among whom 106 were
considered evaluable. Intention-to-treat (ITT) analysis demonstrated that patients fed the EPA/GLA diet developed
less severe sepsis and/or septic shock than patients fed the control diet (26.3% versus 50%, respectively; P =
0.0259), with similar results observed for the evaluable patients (26.4% versus 50.9% respectively; P = 0.0217). The
ITT analysis demonstrated that patients in the study group developed cardiovascular failure (36.2% versus 21%,
respectively; P = 0.0381) and respiratory failure (39.6% versus 24.6%, respectively; P = 0.0362) less often than the
control group. Similarly, when considering only the evaluable patients, fewer patientsdeveloped cardiovascular
failure (20.7% versus 37.7%, respectively; P = 0.03) and respiratory failure (26.4% versus 39.6%, respectively; P = 0.04).
The percentage of patients fed the EPA/GLA diet requiring invasive mechanical ventilation was reduced compared
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reproduction in any medium, provided the original work is properly cited.with controls (ITT patients: 18.9% versus 33.9%, respectively; P = 0.394; evaluable patients: 17.5% versus 34.5%,
respectively; P = 0.295). Patients nourished with the EPA/GLA diet remained in the ICU fewer days than the control
population (ITT patients: 21.1 ICU-free days versus 14.7 ICU-free days, respectively; P < 0.0001; evaluable patients:
20.8 ICU-free days versus 14.3 ICU-free days, respectively; P < 0.0001) and fewer days at the hospital (ITT patients:
19.5 hospital-free days versus 10.3 hospital-free days, respectively; P < 0.0001; evaluable patients: 19.1 hospital-free
days versus 10.2 hospital-free days, respectively; P < 0.001) (all numbers expressed as means). No significant
differences in 28-day all-cause mortality were observed (ITT patients: 26.2% EPA/GLA diet versus 27.6% control diet,
respectively; P = 0.72; evaluable: 26.4 EPA/GLA diet versus 30.18 control diet, respectively; P = 0.79).
Conclusions: These data suggest that EPA/GLA may play a beneficial role in the treatment of enterally fed patients
in the early stages of sepsis without associated organ dysfunction by contributing to slowing the progression of
sepsis-related organ dysfunction, especially with regard to cardiovascular and respiratory dysfunction.
Trial Registration: ClinicalTrials.gov: NCT00981877
Introduction
It has been demonstrated that nutritional support by
feeding patients specialized diets, as a result of its capa-
city to interfere with a variety of biological processes,
can modulate the chain of inflammatory responses [1-3].
Recent pharmaceutical interventions proposed for sepsis
have sought to focus on regulating the chain of pro-
and anti-inflammatory mediators [4,5], which are
responsible for causing the systemic characteristics of
the disease and consequently leading to multiple organ
failure. The inflammatory reaction is capable of activat-
ing the synthesis of several lipid mediators which are
involved in the complex regulation of the inflammatory
process [6].
Lipid mediators are synthesized by three main path-
ways, cyclooxygenase, 5-lipoxygenase and cytochrome
P450, by using fatty acids such as arachidonic acid (AA),
eicosapentaenoic acid (EPA) and g-linolenic acid (GLA)
as substrates [7], but the biological anti-inflammatory
activities of EPA and GLA are far beyond the simple
regulation of eicosanoid production. For instance, EPAs
can affect immune cell responses through the regulation
of gene expression and subsequent downstream events
by acting as ligands for nuclear receptors [8] and as
control transcription factors [9]. EPA can also affect the
activity of the proinflammatory transcription nuclear
factor B( N F - B), which regulates the expression of
many proinflammatory gene-encoding adhesion mole-
cules, cytokines, chemokines and other effectors of the
innate immune response system [10]. Researchers have
recently described that the two main active fish oil phar-
maconutrients, EPA and docosahexaenoic acid, are sub-
strates of two novel classes of mediators called resolvins
and protectins [11,12], which are involved in the resolu-
tion of the inflammatory process [13-15].
In 1999, Gadek and co-workers [16] demonstrated
that the use of a diet enriched with EPA, GLA and anti-
oxidants can improve oxygenation status in patients
with acute respiratory distress syndrome (ARDS). The
same study demonstrated that patients nourished with
this diet spend fewer days in the ICU as well as in the
hospital. This diet was further evaluated in two addi-
tional studies published in 2006 [17,18]. Singer et al.
[17] demonstrated the effectiveness of an EPA/GLA diet
in improving oxygenation status and decreasing the ICU
and hospital length of stay (LOS) of patients with acute
lung injury (ALI). This diet was also associated with
lower mortality rates on the basis of 28-day all-cause
mortality. Similar results were observed by Pontes-
Arruda et al. [18] in which such a diet was fed to
patients with ARDS secondary to severe sepsis and/or
septic shock.
In a recently published meta-analysis of outcomes, the
three above-mentioned studies were combined [19]. For
the patients considered evaluable (n = 296), the use of
an EPA/GLA diet was associated with a 60% reduction
in the risk of 28-day in-hospital all-cause mortality
(odds ratio (OR) = 0.40, 95% confidence interval (95%
CI) = 0.24 to 0.68; P = 0.001). With regard to the effects
of the use of an EPA/GLA diet upon mortality on the
basis of intent-to-treat (ITT) analysis (n = 411 patients),
a4 9 %r e d u c t i o ni nt h er i s ko f2 8 - d a yi n - h o s p i t a la l l -
cause mortality was evident (OR = 0.51, 95% CI 0.33 to
0.79; P = 0.002). Available clinical evidence is also con-
sistent in showing a reduction in time on mechanical
ventilation as well as ICU and hospital LOS. In fact, a
second meta-analysis including data from unpublished
studies [20] demonstrated similar results.
In analyzing the data together, it was clear that feed-
ing patients an EPA/GLA diet was associated with a
reduction in the development of new organ dysfunction.
Although the Singer et al. study [17] did not assess this
variable, both Gadek et al. [16] and Pontes-Arruda et al.
[19] demonstrated reductions in this particular outcome.
Combined, the feeding patients an EPA/GLA diet was
associated with an 83% reduction in the development of
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new organ failure is the pathway that leads patients with
sepsis to severe sepsis and septic shock, it appears logi-
cal to evaluate the possible benefits of treating patients
with this nutritional intervention in the early stages of
sepsis (defined as systemic inflammatory response syn-
drome associated with confirmed or presumed infection
and without any organ failure) as a way to prevent the
evolution or to slow progression of the disease. More-
over, if we consider that the development of multiple
organ failure is associated with increased mortality rates,
we can hypothesize that feeding patients a diet including
an enteral formulation enriched with EPA/GLA might
be a determining factor in reducing the mortality rate.
All previously published trials were performed in criti-
cally ill, mechanically ventilated patients with at least
one organ failure. Since the effects of the EPA/GLA diet
in patients without any organ failure remain uncertain,
the aims of this clinical study were to evaluate the role
of an enteral formulation enriched with EPA/GLA in
patients diagnosed in the very early stages of sepsis,
despite respiratory failure, and to compare the results
with those obtained with the use of a standard ICU for-
mulation, isocaloric and isonitrogenous to the study
diet, and not enhanced with lipids but higher in
carbohydrates.
Materials and methods
Study design and ethical aspects
In this prospective, multicenter, randomized, double-
blinded, controlled trial, we compared the effects of
feeding patients with early sepsis a diet including enteral
nutrition enriched with EPA, GLA and elevated levels of
antioxidant vitamins (Oxepa™; Abbott Nutrition, Chi-
cago, IL, USA) those of an isonitrogenous and isocaloric
control diet (Ensure Plus HN™; Abbott Nutrition, Chi-
cago, IL, USA). The control diet used did not contain
EPA or GLA, but was higher in carbohydrates than the
study diet and therefore was considered a standard ICU
diet. The complete composition of the diets fed to the
patients is given in Table 1. The study was approved by
12 centers in Brazil, and the patients were recruited
from five of these centers during a 21-month period
from 10 July 2007 to 27 April 2009.
This study was approved by the institutional review
boards of each participating institution, by the Brazilian
Federal Commission of Ethics and Research (CONEP)
and by the Brazilian National Agency of Sanitary Vigi-
lance (ANVISA), as required by law, before any patient
enrollment. Informed written consent was obtained
from all patients or from their legal representatives.
This study was performed in accordance with all ethics
statements in the Declaration of Helsinki (52nd General
Assembly of the World Medical Association, Edinburgh,
Table 1 Composition of the study and control diets used
Diet components Study diet
(Oxepa™)
a
Control diet (Ensure
Plus HN™)
a
Protein
Percentage of
total calories
16.7 16.7
Concentration, g/L 62.5 62.7
Sources 87% sodium
caseinate
13% calcium
caseinate
73% sodium caseinate
11% calcium caseinate
16% soy protein isolate
Carbohydrates
Percentage of
total calories
28.1 54.3
Concentration, g/L 105.5 204
Sources 45% maltodextrin
55% sucrose
100% maltodextrin
Lipids
Percentage of
total calories
55.2 29.0
Concentration, g/L 93.7 49.1
Sources 31.8% canola oil
25% medium chain
triglycerides
20% borage oil
20% fish oil
3.2% soy lecithin
50% high oleic
safflower oil
30% canola oil
20% medium chain
triglycerides
Ω-6:Ω-3 ratio 1.85:1 3.8:1
Ω-3, g/L 10 1.5
Eicosapentaenoic acid
(EPA), g/L
4.5 0
g-Linolenic acid (GLA),
g/L
4.3 0
Docosahexaenoic acid
(DHA), g/L
2.0 0
Vitamins
E, IU/L 320 39
C, mg/L 840 130
b-carotene, mg/L 670 345
Taurine, mg/L 320 150
L-carnitine, mg/L 120 120
A, IU/L 12,000 4,167
D, IU/L 430 400
K1, μg/L 100 80
Folic acid, μg/L 420 400
Thiamine, mg/L 3.2 2.8
Riboflavin, mg/L 3.6 3.4
B6, mg/L 4.3 3.9
B12, mg/L 6.0 4.0
Niacin, mg/L 29 29
Choline, mg/L 640 800
Biotin, μg/L 1 72
Pantothenic acid,
mg/L
13 13
Trace minerals
Na, mg/L 1,310 1,400
K, mg/L 1,960 1,650
Cl, mg/L 1,690 1,450
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Page 3 of 15UK, October 2000) and the Nuremberg Code [21]. All
included patients were treated in accordance with the
Surviving Sepsis Campaign guidelines for the manage-
ment of severe sepsis and septic shock [22], which
means that adequate initial resuscitation was adminis-
tered to all patients with sepsis-induced tissue hypoper-
fusion, in accordance with the protocol described by
Rivers et al. [23], and broad spectrum antibiotics were
administered within the first hour of ICU admission.
Study patients
The study inclusion criteria were that patients had to be
older than 18 years of age, at the ICU with a clinical diag-
nosis of early sepsis and required enteral nutrition. A 36-
hour window was allowed to establish a clinical diagnosis
of sepsis, obtain the necessary written informed consent
from the patients and randomize the patients. The diagno-
sis of sepsis was made on the basis of the criteria pre-
viously defined by Bone et al. [24] and as modified by
Bernard et al. [25]. The following were considered exclu-
sion criteria: severe sepsis (sepsis associated with at least
one organ failure) and septic shock (sepsis associated with
hypotension despite adequate fluid resuscitation) at base-
line, a clinical diagnosis of sepsis for more than 36 hours,
pregnancy or breastfeeding, patients younger than 18
years of age, significant limitation of survival prognosis
(patients expecting with a life survival expectancy less than
28 days because of a chronic and/or incurable disease such
as uncontrolled cancer or other terminal disease), preexist-
ing chronic renal insufficiency and need of hemodialysis or
peritoneal dialysis, body mass index (BMI) ≥ 29, acute
pancreatitis without established origin, participation in
other clinical trials less than 6 months before this trial,
head trauma with a Glasgow Coma Scale score ≤ 5, recent
stroke or subarachnoid hemorrhage (less than 3 months),
severe immunologic suppression (defined as a leukocyte
count below 5,000 cells/mm
3) ,H I Vi n f e c t i o n ,n oi n d i c a -
tion for enteral feeding or imminent need for parenteral
nutrition, partial parenteral nutrition to achieve caloric
goals, presence of uncontrolled diarrhea, recent gastroin-
testinal bleeding, physician’s decision to exclude patients
on the basis of the study protocol, or the presence of
respiratory failure (defined as evidence of acute pulmonary
dysfunction with a ratio of partial pressure of oxygen to
fraction of inspired oxygen (PaO2/FiO2 ratio) < 300 and, if
measured, pulmonary capillary wedge pressure not sugges-
tive of central volume overload). Mechanical ventilation at
baseline per se was not considered a reason for exclusion
as long as the patient maintained a PaO2/FiO2 ratio not
indicative of respiratory failure.
Randomization and study diet administration
Patients were randomized at a ratio of 1:1 using a web-
based central randomization system. Patients, families
and caregivers were blinded to the type of diet being
delivered. All data were inserted into a web-based clinical
research form located in a secure server using an
encrypted and dedicated website. Randomization was
performed using blocks of randomization. Each block
used an algorithm with different sizes and sequences of
randomization to guarantee an adequate balance between
the two study groups at any time, independently of the
number of patients enrolled. The caloric goal was auto-
matically calculated by using the Harris Benedict Equa-
tion × 1.3, taking into consideration the information
inserted (such as age, weight and height). After randomi-
zation, the group information (study or control) and the
dietary caloric goals (measured in kilocalories per liter or
in milliliters) were sent by personal email message to the
nonblinded person in the center in which the patient was
included. Once the patient was randomized, a 12-hour
window was allowed to start the enteral diet; therefore,
each institution had a 48-hour window within which to
begin the study protocol including the 36 hours required
to identify the patient, obtain the patient’s written
informed consent and randomize the patient, with an
additional 12 hours to start the diet) (see Figure 1). Infor-
mation was inserted daily regarding the exact date and
time when the diet started as well as the patient’s daily
caloric intake. Patients were excluded from the trial on
the basis of a protocol violation if the enteral diet was
not started within 12 hours after randomization.
Study and control diets were similar in consistency
and color. To maintain adequate blinding, the diets
were poured into similar and sealed containers before
being delivered to the ICU. The containers were con-
nected to an infusion pump (Patrol Enteral Feeding
Pump; Abbott Nutrition, Chicago, IL, USA) using a
closed system to prevent any detection of the diet smell
Table 1 Composition of the study and control diets used
(Continued)
Ca, mg/L 1,060 1,000
P, mg/L 1,000 1,000
Mg, mg/L 320 310
I, μg/L 160 150
Mn, mg/L 5.4 5.0
Cu, mg/L 2.2 2.5
Zn, mg/L 18 19
Fe, mg/L 20 22
Se, μg/L 130 70
Cr, μg/L 160 100
Mo, μg/L 130 150
Caloric density, kcal/
mL
1.5 1.5
Osmolarity, mOsmol/L 385 392
aOxepa™ and Ensure Plus HN™ are trademarked products of Abbott
Laboratories (Chicago, IL, USA).
Pontes-Arruda et al. Critical Care 2011, 15:R144
http://ccforum.com/content/15/3/R144
Page 4 of 15by the blinded subjects. Enteral feeding was delivered at
a constant rate to achieve a minimum of 50% basal
energy expenditure (BEE) × 1.3 within the first 24
hours. If well tolerated, enteral nutrition was advanced
to achieve a minimum of 75% of BEE × 1.3 within 72
hours. Diets were delivered continuously without night
pause and using the same protocol in all participating
institutions. The enteral diets were delivered for a total
of seven days or until they were interrupted at the phy-
sician’s discretion or because of the development of any
adverse event that could be related to the enteral feed-
ing. The diet could also be interrupted if there was an
indication to start oral feeding or parenteral nutrition.
After the diet was interrupted, and if the patient was
still in need of enteral nutrition, each individual institu-
tion was allowed to freely select the most appropriate
diet to continue the enteral nutrition therapy. The day
on which patients started receiving the diet was consid-
ered study day 1.
Laboratory data, outcome measures and statistical
analysis
Blood samples were obtained for routine laboratory test-
ing on a daily basis. Severity scores, including the Acute
Physiology and Chronic Health Evaluation II (APACHE
II) score and the Sequential Organ Failure Assessment
score (SOFA), were automatically calculated by the web-
based system, taking into consideration the individual
values inserted for each patient to avoid possible human
errors in the calculations of the severity scores.
The primary issue was to determine the development
of severe sepsis and septic shock during a 28-day fol-
low-up period. To achieve this goal, a daily evaluation
regarding the development of individual organ failure
was performed. The criteria used to define each organ
failure are given in Table 2. If the patient developed at
least one organ failure, the patient was considered to
have developed severe sepsis. If refractory hypotension
was identified, the patient was counted as having devel-
oped septic shock. Secondary issues included ICU and
hospital LOS, mechanical ventilation support, develop-
ment of individual organ failure and 28-day all-cause
mortality.
At the conclusion of the study, the whole database
and the source documentation were independently
audited to ensure the quality of the information col-
lected, and the database was analyzed by an independent
statistical company (Bioestatística, Montreal, QC,
 
Figure 1 Participant flow diagram. BEE = basal energy expenditure.
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the two groups using the c
2 test or Fisher’s exact test as
appropriate [26]. Quantitative normally distributed vari-
ables between the groups were compared using an
unpaired two-sample t-test. For quantitative non-nor-
mally distributed data, the nonparametric Wilcoxon
rank-sum test was used [26]. Normality was assessed by
using the Shapiro-Wilk test [26,27]. Normally distribu-
ted data are reported as means with standard deviations
(SDs), and non-normally distributed data are expressed
as medians and interquartile ranges (IQRs, 25th to 75th
percentiles). Categorical variables are expressed as num-
bers and percentages.
Estimates of survival curves during a 28-day follow-up
period were calculated according to the Kaplan-Meier
product limit method [28] and compared by using the
log-rank test [29]. All statistical analyses were performed
using SAS version 9.2 software (SAS Institute, Inc., Cary,
NC, USA). All P values are two-tailed. P < 0.05 was con-
sidered statistically significant.
Results
Patients and demographic characteristics
A total of 115 patients were included, but nine patients
(four in the study group and five in the control group)
were excluded on the basis of protocol violation because
their diet was not started within the 12-hour window,
leaving 106 patients to be evaluated: 53 in the study
group and 53 in the control group. The population of
patients included was considered well balanced in terms
of baseline demographic characteristics, including sever-
i t ys c o r e s .T h ep a t i e n t s ’ median ages were 70 (IQR 64
to 78) years in the study group and 72 (IQR 65 to 82)
years in the control group (P >0 . 0 5 ) ,w i t has l i g h t l y
higher number of males than females in both groups.
The severity scores were considered quite high for both
populations on the basis of APACHE II scores (median
19.5 (IQR 17 to 25) in the study group versus 20 (IQR
16 to 23) in the control group), SOFA scores (median
5.5 (IQR 4 to 9) in the study group versus 6 (IQR 4 to
8) in the control group) and Multiple Organ
Dysfunction Score (median 4 (IQR 3 to 6) for the study
group and 4 (IQR 3 to 5) for the control group) (all P >
0.05). Included patients also presented similar numbers
of baseline comorbidities. The baseline population char-
acteristics of both groups are given in Table 3.
Dietary intake
The nutritional status of all patients was evaluated by
using the Subjective Global Assessment (SGA) at baseline.
The majority of the population included was considered to
have some degree of malnourishment at baseline on the
basis of the SGA. Proportions of 62.3% of the patients in
the study group and 52.8% of the patients in the control
group were considered either moderately undernourished
or severely undernourished, but the differences between
the groups in terms of nutritional status were not consid-
ered to be of statistical significance. There were no signifi-
cant differences in terms of calculated caloric goals, daily
volume in milliliters and total caloric intake per day. The
study group received more lipids than the control group
(mean 96.0 ± 37.2 g/day in the study group versus 49.8 ±
19.0 g/day in the control group; P < 0.0001), whereas the
control population received more carbohydrates than the
study group (mean 205.6 ± 77.4 g/day versus 104.2 ± 38.9
g/day; P < 0.0001). The nutritional parameters and dietary
intake data are given in Table 4.
The incidence of diarrhea and vomiting was also eval-
uated. A total of two patients in the study group (3.8%)
and three patients in the control group (5.7%) experi-
enced vomiting. In addition, four patients in the study
group (7.5%) and seven patients in the control group
(13.2%) had uncontrolled diarrhea. The differences
between the two groups were not considered statistically
significant in terms of either vomiting (P = 0.74) or diar-
rhea (P =0 . 4 3 ) .D u r i n gt h i ss t u d y ,n os e r i o u sa d v e r s e
events were recorded.
Primary outcome: development of severe sepsis and
septic shock
The population nourished with EPA/GLA developed less
severe sepsis and septic shock than the patients
Table 2 Criteria used to define individual organ dysfunction
a
Type of
dysfunction
Definition
Cardiovascular Systolic arterial pressure ≤ 90 mmHg after adequate fluid resuscitation
Respiratory PaO2/FiO2 ratio ≤ 300 and, if measured, pulmonary capillary wedge pressure not suggestive of central volume overload
Hematologic Platelet count ≤ 100,000/mm
3 or 50% drop in the past 72 hours or relevant changes in coagulation profile (INR > 1.5 or aPTT >
60 seconds)
Renal Urine output < 0.5 mL/kg/hour for at least 2 hours, even after fluid resuscitation or creatinine > 2.0 mg/dL
Metabolic pH < 7.30 or base excess less than -5 mEq/L with plasma lactate > 1.5 × normal value
Hepatic Total bilirubin > 2.0 mg/dL or 35 mmol/L
aPaO2/FiO2 ratio = ratio of partial pressure of oxygen to fraction of inspired oxygen; INR = International Normalized Ratio; aPTT = activated partial thromboplastin
time.
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primary outcome including all 115 patients demon-
strated that more patients in the control group than in
the study group evolved to severe sepsis and/or septic
shock (29 patients (50%) in the control group versus 15
patients (26.3%) in the study group; P = 0.0259), with 3
patients (5.3%) developing severe sepsis and 12 patients
(21.0%) developing septic shock in the study group ver-
sus 8 patients (13.8%) developing severe sepsis and 21
patients (36.2%) evolving to septic shock in the control
group. Considering only the evaluable patients (n =
106), a total of 26.4% of the patients in the study group
evolved to more severe forms of sepsis as compared to
51% in the control group (P = 0.0217) (see Figure 2). In
the study group, in 5.7% of the patients, their conditions
evolved to severe sepsis, and in 20.7% the patients’ con-
dition evolved to septic shock. In the control group,
13.3% of the population developed severe sepsis and
37.7% developed septic shock.
With regard to the development of individual dysfunc-
tions, it is notable that the observed difference is due
basically to more development of cardiovascular and
respiratory failure in the control group. The ITT analy-
sis demonstrated that more patients in the control
Table 3 Baseline demographic characteristics of the patients
a
Characteristics Study (n = 53) Control (n = 53) P value
Age, years
b 70 (64 to 78) 72 (65 to 82) 0.3729
Sex
Males, n (%) 32 (60.4) 29 (54.7) 0.6826
Females, n (%) 21 (39.6) 24 (45.3) 0.7726
Weight, kg 59.3 ± 12.5 61.2 ± 11.7 0.4243
Height, cm 166.2 ± 11.4 167.7 ± 10.4 0.4749
APACHE II score
b 19.5 (17 to 25) 20 (16 to 23) 0.5291
SOFA score
b 5.5 (4 to 9) 6 (4 to 8) 0.7991
MODS score
b 4 (3 to 6) 4 (3 to 5) 0.6106
Lactate, mmol/L
b 3.75 (2.9 to 4.65) 3.7 (2.8 to 4.3) 0.7181
Blood glucose, mg/dL
b 103 (89 to 149) 102 (87 to 125) 0.6109
Temperature, °C
b 39.4 (38.2 to 39.8) 38.9 (37.2 to 39.5) 0.0780
GCS score 10.1 ± 2.2 10.8 ± 2.1 0.1661
White blood cells, 1 × 10
9 cells/L 19.3 ± 0.9 20.7 ± 0.7 0.4187
Platelets, 1 × 10
9 cells/L
b 198 (144 to 259) 211 (178 to 256) 0.3580
Serum creatinine, mg/dL
b 1.15 (0.9 to 1.6) 0.9 (0.8 to 1.3) 0.9088
Total bilirubin, mg/dL
b 0.9 (0.7 to 1.3) 0.8 (0.7 to 1.5) 0.7739
Serum Na, mEq/L
b 139 (133 to 145) 135 (137 to 144) 0.9053
Serum K, mEq/L 3.9 ± 0.7 4.0 ± 0.8 0.6718
Patients supported with MV, n (%)
c 1 (1.9) 2 (3.8) 0.5172
Patients treated with sedatives, n (%) 3 (5.7) 5 (9.4) 0.1280
Baseline comorbidities, n (%)
Recent surgery (< 3 months) 6 (11.3) 9 (16.9) 0.4008
History of alcoholism 10 (18.9) 8 (15.1) 0.6027
Asthma 12 (22.6) 17 (32.1) 0.2705
Diabetes 10 (18.9) 9 (16.9) 0.7988
COPD 11 (20.75) 12 (22.6) 0.8122
Cancer 4 (7.5) 4 (7.5) 0.6425
Thromboembolism 1 (1.9) 1 (1.9) 0.7525
History of illicit drug use 4 (7.5) 2 (3.8) 0.6425
Primary source of infection, n (%)
Lungs 38 (71.7) 33 (62.3) 0.2893
Abdomen 6 (11.3) 8 (15.1) 0.5311
Urinary tract 4 (7.6) 2 (3.7) 0.1980
Other 5 (9.4) 10 (18.9) 0.0815
aAPACHE II = Acute Physiology and Chronic Health Evaluation II; SOFA = Sequential Organ Failure Assessment; MODS = Multiple Organ Dysfunction Score; GCS =
Glasgow Coma Scale; MV = mechanical ventilation; COPD = chronic pulmonary obstructive disease. Data are presented as medians (interquartile range, 25th to
75th percentiles), and P values were calculated using the Wilcoxon rank-sum test.
bDistributions considered non-normal on the basis of the Shapiro-Wilk test.
cAll
MV patients were supported with noninvasive mechanical ventilation.
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Page 7 of 15Table 4 Nutritional parameters of the included patients
a
Variable Study (n = 53) Control (n = 53) P value
SGA nutritional status, n (%)
Well-nourished 20 (37.7) 25 (47.2) 0.4672
Moderately undernourished 22 (41.5) 21 (39.6) 0.7983
Severely undernourished 11 (20.8) 7 (13.2) 0.6974
Type of enteral feeding, n (%)
Gastric 25 (47.2) 23 (43.4) 0.5112
Duodenal/jejunal 19 (35.8) 21 (39.6)
Gastrostomy 6 (11.3) 5 (9.4)
Jejunostomy 3 (5.7) 4 (7.6)
Daily nutritional values
Days receiving diet, n 6.09 ± 0.4 6.17 ± 0.8 0.4512
Calculated caloric goal, kcal/day
b 1,557 (1,367 to 1,812) 1,560 (1,422 to 1,820) 0.4827
Calculated caloric volume, mL/day
b 1,038 (911 to 1,208) 1,040 (948 to 1,213) 0.9600
Calories, kcal/day
b 1,538 (1,295 to 1,890) 1,523 (1,370 to 1,950) 0.3974
Volume, mL/day
b 1,025 (863 to 1,260) 1,015 (913 to 1,300) 0.3533
Lipids, g/day 96.04 ± 37.2 49.8 ± 19.0 < 0.0001
Carbohydrates, g/day 104.2 ± 38.9 205.6 ± 77.4 < 0.0001
Proteins, g/day 63.4 ± 22.8 62.6 ± 24.3 0.3188
EPA, g/day 4.6 ± 1.8 0 < 0.0001
GLA, g/day 4.4 ± 1.7 0 < 0.0001
DHA, g/day 2.05 ± 0.7 0 < 0.0001
Time to start enteral feeding, hours 8.4 ± 2.6 7.6 ± 3.1 0.2833
Time to reach 75% of caloric goal, hours 35.2 ± 8.7 32.0 ± 6.4 0.0871
aSGA = Subjective Global Assessment; EPA = eicosapentaenoic acid; GLA = g-linolenic acid; DHA = docosahexaenoic acid. Data are presented as medians
(interquartile range, 25th to 75th percentiles), and P values were calculated using the Wilcoxon rank-sum test.
bDistributions considered non-normal on the basis
of the Shapiro-Wilk test.
Figure 2 Graph showing incidence of severe sepsis and septic shock.
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Page 8 of 15group than in the study group developed respiratory
failure (23 patients (39.6%) versus 14 patients (24.6%),
respectively; P = 0.0362) and cardiovascular failure (21
patients (36.2%) versus 12 patients (21.0%), respectively;
P = 0.0381), with no significant differences observed in
terms of coagulation failure (eight patients in the study
group versus nine in the control group, respectively; P =
0.81), renal failure (six patients in the study group ver-
sus six in the control group, respectively; P = 0.63),
metabolic failure (7 patients in the study group versus
13 in the control group, respectively; P = 0.07) or hepa-
tic failure (four patients in the study group versus five
in the control group, respectively; P = 0.74). Considering
only the evaluable patients (n = 106), 11 patients in the
study group developed cardiovascular failure as com-
pared to 20 patients in the control group (P = 0.03).
Additionally, 14 patients in the study group developed
respiratory failure compared to 21 patients in the con-
trol group (P = 0.04). No significant differences were
found in terms of metabolic, renal, hepatic or coagula-
tion failure (Figure 3).
Secondary outcomes
With regard to the results for all included patients, three
patients required noninvasive mechanical ventilation at
baseline, including one in the study group and two in
the control group (see Table 3), although they did not
fulfill the criteria for respiratory failure (all included had
PaO2/FiO2 ratios > 300). The ITT analysis demonstrated
that invasive mechanical ventilation was required by
more patients in the control group than in the study
group (20 patients (34.5%) versus 10 patients (17.5%),
respectively; P = 0.295) and for a median of 7 days
(interquartile range (IQR) 4 to 12) days in the study
group and 15 days (IQR 8 to 21) in the control group
(P = 0.003). Patients in the control group had fewer
ICU-free days than the study group (means ± SD: 14.7
± 5.1 days versus 21.1 ± 4.7 days, respectively; P <
0.001) as well as fewer hospital-free days than the study
group (means ± SD: 10.3 ± 8.6 days versus 19.5 ± 7.8
days; P <0 . 0 0 1 ) .T h ea n a l y s i so ft h e1 0 6e v a l u a b l e
patients showed that more patients in the control group
than in the study group required invasive mechanical
ventilation (18 patients in the control group versus 10
patients in the study group; P = 0.0394), but no differ-
ences were found in terms of noninvasive mechanical
ventilation (five patients in the study group versus six
patients in the control group; P > 0.05). The patients
nourished with EPA/GLA required mechanical ventila-
tion for a shorter time than the control patients (median
7 days (IQR 4 to 7) in the study group versus 15 days
(IQR 9 to 21) in the control population; P = 0.003). In
addition, patients who were fed the study diet remained
in the ICU for fewer days (median 7 (IQR 4 to 12) days
in the study group versus 13 days (IQR 9 to 18) in the
control population; P < 0.0001), as well as fewer days at
the hospital (9 days (IQR 6 to 14) in the study group
versus 19 days (IQR 13 to 24) in the control group; P <
0.0001) (see Table 5). Differences were also significant
when expressed in terms of ICU-free and hospital-free
Figure 3 Graph showing the development of individual system failures.
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Page 9 of 15days. The mean total ICU-free days were 20.8 ± 3.9 in
the population nourished with EPA/GLA versus 14.3 ±
5 . 1i nt h ec o n t r o lp o p u l a t i o n( P < 0.001). The mean
total hospital-free days were 19.1 ± 6.3 in the study
group and 10.2 ± 8.2 in the control group (P < 0.001).
No patients requiring vasopressors or inotropic drugs
were included at baseline. During the 28-day follow-up
period, dobutamine was required for 9 patients (17%) in
the study group and 13 patients (24.5%) in the control
group (P = 0.34), with similar daily doses used for both
groups (9.96 μg/kg/minute for the study group and 9.57
μg/kg/minute for the control group; P = 0.77). Dopa-
mine was used to treat 12 patients (22.6%) in the study
group and 17 patients (32.1%) in the control group (P =
0.28), with mean daily doses of 23.4 μg/kg/minute in the
study group and 21.5 μg/kg/minute in the control group
(P = 0.87). Norepinephrine was used to treat 9 patients
(17%) in the study group and 11 patients (20.7%) in the
control group (P = 0.61), with mean daily doses of 2.2
μg/kg/minute in the study group and 1.8 μg/kg/minute
in the control group (P = 0.81).
No differences were found in the ITT analysis of 28-
day all-cause mortality (n = 115). By day 28, 15 of 57
patients in the study group had died and 16 of 58
patients in the control group had died (P =0 . 7 2 ) .S i m i -
larly, no difference was found in the 28-day all-cause
mortality of the evaluable patients (n = 106) (Figure 4),
among whom 39 patients (73.5%) in the study group
and 37 patients (69.8%) in the control group were alive
after 28 days. The log-rank test analysis indicated that
the difference was not significant (P = 0.79).
Discussion
Currently available strategies for the treatment of
patients with sepsis focus on the management of the
more severe forms of the disease (severe sepsis and/or
septic shock), when the patients already have multiple-
system organ dysfunctions, which is always associated
with elevated death risk [30,31]. The contradiction is
that there is also a consensus that, when treating
patients with sepsis, most, if not all, available strategies
are time-dependent [32].
Unfortunately, information about possible strategies to
be applied in the early stages of sepsis is extremely lim-
ited, as is the number of trials evaluating possible thera-
pies this early in the disease time line. The main
purpose, and probably the most interesting characteris-
tic of the present trial, was to apply a nutritional strat-
egy that has proven to be of great value in the
management of patients with late sepsis-associated
respiratory failure [1], and is associated with an impor-
tant reduction in the development of new organ failures
[20], early in the evolutionary stage of sepsis when no
organ dysfunction has been identified and to test
whether this nutritional strategy can be used to help
slow the progression of the disease.
In this study, we found an association of the use of an
EPA/GLA diet with reduced incidence of severe sepsis
and/or septic shock. Although the mechanisms underly-
ing the results of the present trial are unclear, there are
several possible roles associated with EPA, GLA and
antioxidants which, acting alone or together, may help
us to understand how this diet can lead to the observed
effects, among them being the regulation of AA levels in
the inflammatory cell membranes, downregulation of
NF-B, lower production of inflammatory eicosanoids,
antioxidant-mediated reduction in overall reactive oxy-
gen species levels and a quicker recovery from inflam-
mation due to production of resolvins and protectins,
among several others.
In this trial, we used a control diet different from
those used in previously published works [16-18]. Our
control diet was not enhanced with lipids but was
higher in carbohydrates and was considered a standard
ICU diet. The reason for our use of that control diet
was that one major focus of criticism of previous work
is precisely the control diet that was used (Pulmocare;
Abbott Nutrition). Maybe the main reason for such cri-
ticism is that a high-lipid enteral diet is not considered
by many to be a standard diet for critically ill patients.
It is a common misunderstanding that enteral formulas
enriched with Ω-6 lipids such as linoleic acid (LA, or
18:2n6; for example, from corn oil) can produce upregu-
lation of the inflammatory response and, for that reason,
such formulas may not be used to feed patients with
hyperinflammatory diseases. Production of AA from LA
involves three key enzymatic steps: Δ-6-desaturation to
form 18:3n6 (GLA), followed by elongation to 20:3n6
(dihomo-GLA (DGLA)) and a Δ-5-desaturation step to
produce 20:4n6. Thus, LA-enriched formulas cannot
worsen inflammation simply because the activity of the
enzymes Δ-5-desaturase and Δ-6-desaturase are severely
Table 5 Use of hospital resources
a
Variable Study (n =
53)
Control (n =
53)
P
value
Mechanical ventilation support, n (%)
Invasive 10 (18.9%) 18 (34%) 0.03984
Noninvasive 5 (9.4%) 6 (11.3%) 0.7501
Duration, days
Mechanical ventilation
support
b
7 (4 to 12) 15 (9 to 21) 0.0033
ICU stay
b 7 (4 to 12) 13 (9 to 18) <
0.0001
Hospital stay
b 9 (6 to 14) 19 (13 to 24) <
0.0001
aData are presented as medians (interquartile range, 25th to 75th percentiles),
and P values were calculated using the Wilcoxon rank-sum test.
bDistributions
considered non-normal on the basis of the Shapiro-Wilk test.
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Page 10 of 15compromised during critical illness by the release of
stress and catabolic hormones (for example, glucocorti-
coids and catecholamines) [33,34] limiting the ability to
form AA despite the provision of LA [35]. GLA is a
metabolite of LA that can bypass the decreased expres-
sion of Δ-6-desaturase. Its elongation product, DGLA, is
incorporated into the inflammatory cell membranes, and
the formation of DGLA suppresses leukotriene biosynth-
esis and can be metabolized to form prostaglandin E1,a
potent pulmonary vasodilator [36,37]. DGLA is also
metabolized by 5-lipoxygenase to form 15-hydroxyeico-
satrienoic acid, which inhibits the formation of leuko-
triene B4. In fact, an enteral diet enriched with GLA
cannot increase AA levels in immune cell membranes
[38] and, on the other hand, can increase anti-inflamma-
tory activity by incorporating DGLA into the immune
cell membranes. Despite all of the above-mentioned evi-
dence, the previous criticism of other studies highlights
the importance of this trial as the first one to demon-
s t r a t eap o s i t i v er e s u l ti nt erms of primary and second-
ary outcomes comparing the EPA/GLA diet with a
standard ICU formula.
In this study, we report a reduction in both ICU and
hospital LOS for patients fed a diet with EPA/GLA
compared to the control population. The differences
represent a mean of 6.5 additional ICU-free days and
8.9 additional hospital-free days associated with the use
of the study diet. These results are in accord with pre-
viously published studies [16-18] in which EPA/GLA
diets were used to treat critically ill patients requiring
mechanical ventilation, all of which reported reductions
in ICU and hospital LOS. In fact, a recent meta-analysis
[19] associated the use of EPA/GLA with a mean of 4.3
more ICU-free days compared to patients fed a control
diet. Sepsis represents an important financial burden on
the healthcare system [39,40], and any reduction in
terms of LOS must be considered to have a potential
economic impact regarding reductions in the overall
cost of care.
It is important to note that the reported number of
patients requiring mechanical ventilation (invasive or
noninvasive) was slightly different in the study groups
with regard to the number of patients considered to
have developed respiratory failures since the end of the
Figure 4 Kaplan-Meier survival curves graphed for 28-day all-cause mortality.
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Page 11 of 15study. The reason for that finding was that, during the
28-day follow-up period, one patient in the study group
and three patients in the control group required nonin-
vasive mechanical ventilation but did not fulfill the
PaO2/FiO2 ratio criterion for respiratory failure.
Previously published works [17,18] and the present
study have many relevant characteristics in common.
They all used a study diet containing carbohydrates and
proteins together with high levels of EPA/GLA. They all
started enteral nutrition as early as possible and deliv-
ered the diet continuously using an enteral feeding
pump. In a recent study (the EDEN-Omega Study) con-
ducted by the EDEN-Omega NHLBI ARDS Network,
investigators reported different findings when treating
critically ill patients [41]. They found no benefit in using
a module containing EPA/GLA to treat patients requir-
ing mechanical ventilation, and the study was stopped
because of futility. Comparison of the EDEN-Omega
Study with the previously published works can lead to
dangerous misinterpretation of the current evidence.
First and foremost, the patients enrolled in the EDEN-
Omega study received a bolus of EPA/GLA twice daily,
not an enteral formula containing EPA/GLA as part of
it. It is uncertain whether these pharmaconutrients act
differently if not provided using continuous feeding and
as part of an enteral nutrition formula. Absorption of
individual macronutrients (such as lipids) at the intest-
inal level can be drastically affected by the presence or
absence of other nutrients. Additionally, it has been
demonstrated [42] that the delivery of an EPA/GLA diet
by continuous feeding can produce important changes
in the production of inflammatory mediators associated
with modulation of plasma phospholipid levels. It is not
clear whether a bolus of EPA/GLA given twice daily can
provide similar changes in plasma phospholipids. Unfor-
tunately, to date, the EDEN-Omega NHLBI ARDS Net-
work investigators have not made publicly available the
plasma phospholipid measurements of the patients
included in the EDEN-Omega study, data that are of
pivotal importance to allow a fair trial comparison
between their trial and those previously published.
Moreover, the EDEN-Omega study did not control for
several other variables, including the different levels of
other macronutrients (such as proteins) in the underly-
ing diets fed to their patients, producing a huge source
of bias in their data. Finally, the EDEN-Omega study
was not designed as an early intervention trial, but was
in fact an early versus late intervention study, whereas
early enteral feeding was described as a key factor in all
previous trials. The currently available nutrition guide-
lines continue to unanimously recommend the use of an
EPA/GLA diet in critically ill and mechanically venti-
lated patients with ALI/ARDS [1,20]; therefore, not to
use this strategy in the indicated population of patients
merely on the basis of the results of an unpublished sin-
gle trial in which so many important questions remain
to be answered does not appear to be justifiable.
Interaction between fish oil and sepsis is very complex
and variable, depending on the dose administered and
probably the route of administration as well. Most of
the available evidence associated with the benefits of
fish oil was produced when this active pharmaconutrient
was used as part of enteral nutrition formulations. How-
ever, the number of trials testing parenterally adminis-
tered fish oil in a variety of clinical situations, including
sepsis, is growing [43,44]. For instance, in a recently
published study using a fish oil-based lipid emulsion in
patients with sepsis, Barbosa and co-workers [45]
demonstrated significant improvements in the PaO2/
FiO2 ratio that were similar to the effects reported with
the use of enteral nutrition.
Although in the present study we have demonstrated a
reduction in the development of cardiovascular and
respiratory failure in the patient population nourished
with EPA/GLA as compared to the control population,
this was not associated with a significant reduction in
mortality. The probable reason for this finding is that
this study included patients with early sepsis and no
organ dysfunction, a clinical situation usually associated
with lower mortality rates than are found in patients
with severe sepsis and/or septic shock [46]. The sample
size of this trial was not calculated to demonstrate mor-
tality differences, and this particular variable should be
evaluated in future studies.
Some important limitations need to be considered
when evaluating the results of the present study. One of
the most important is that this study included only
those patients in need of enteral nutrition. During the
enrollment of the patients, the investigators considered
this to be very relevant and to represent a limitation in
terms of the number of potential patients who could be
included in this trial, since most patients whom we
found to be in the early stages of sepsis did not require
enteral nutrition, being able to receive oral feeding. In
addition, the study included only patients at the ICU,
which reduced even more the number of potential
patients to be included, since the majority of the
patients with early sepsis are usually not at the ICU but
in the general wards. As a result of these important lim-
itations, we believe that the population of patients
included in this study was somehow selected, being con-
stituted by elderly patients, most of whom were already
receiving treatment and enteral feeding at their homes
because of previous limitations such as stroke and even-
tually developing diseases such as community-acquired
pneumonia, therefore requiring hospital treatment. In
addition, this study excluded patients with a BMI ≥ 29,
and for this reason generalization of the results to the
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was not possible to report changes in the Δ or compo-
nent SOFA scores, since this trial was not designed to
collect daily SOFA scores. Therefore, it is uncertain
whether the observed reduction in the development of
severe sepsis and/or septic shock is associated with
reductions in the SOFA score over time. This associa-
tion represents an important variable to be evaluated in
future trials in which an EPA/GLA diet is fed to septic
patients.
It will be important to produce further evidence and
reproduce the present work in a more broad population
of patients in the early stages of sepsis using an EPA/
GLA diet, maybe as an oral supplement, and not deli-
vering these pharmaconutrients only when an enteral
feeding tube is in place.
Conclusions
The present study presents evidence that enteral nutri-
tion with EPA/GLA and elevated antioxidants, when
used in the early stages of sepsis in patients without any
organ failure and in need of enteral nutrition, can play a
beneficial role by slowing the progression of the disease
to severe sepsis and septic shock. The possible benefit
of EPA/GLA supplementation in patients receiving oral
feeding needs further evaluation.
Key messages
￿ Although EPA/GLA is currently recommended for cri-
tically ill, mechanically ventilated patients with ALI/
ARDS in accordance with international guidelines, there
is no evidence that this diet has any benefit when used
in the early stages of sepsis.
￿ This report describes a prospective, multicenter,
double-blinded, controlled study designed to evaluate
the effects of enteral nutrition with EPA/GLA in criti-
cally ill patients with early sepsis without organ failure.
￿ When used in the above-mentioned patient popula-
tion, enteral nutrition enriched with EPA/GLA was
associated with less development of severe sepsis and/or
septic shock, primarily because of the reduced number
of cardiovascular and respiratory failures in the study
population.
￿ An additional benefit was found in terms of reduced
hospital and ICU LOS, which represents an important
reduction in the overall cost of care for the treatment of
this patient population.
￿ No effect was observed with regard to 28-day all-
cause mortality.
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